SANUWAVE Health, Inc. (OTCMKTS:SNWV) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On March 5, 2019, SANUWAVE Health, Inc., a Nevada corporation (the “Company”), posted to its corporate website a presentation to be given by the management of the Company to investors to provide an overview of the Company. A copy of management’s presentation slides are attached hereto as Exhibit 99.1.
The information in this Item 7.01 of this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
Management Presentation for investor meetings dated March 2019.
SANUWAVE Health, Inc. Exhibit
To view the full exhibit click
About SANUWAVE Health, Inc. (OTCMKTS:SNWV)
SANUWAVE Health, Inc. is an acoustic pressure shock wave technology company using a system of noninvasive, high-energy, acoustic pressure shock waves for indications, such as regenerative medicine and other applications. The Company is focused on regenerative medicine utilizing noninvasive (extracorporeal), acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, enabling to restore the body’s normal healing processes and regeneration. It is focused on developing its Pulsed Acoustic Cellular Expression (PACE) technology to activate healing in wound conditions.